PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29277814
OWN - NLM
STAT- In-Process
LR  - 20171226
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in
      Metastatic Colorectal Cancer.
PG  - 491-499
AB  - AIM: This study aimed to clarify the predictive impact of visceral fat on
      response to bevacizumab in patients with metastatic colorectal cancer (mCRC).
      PATIENTS AND METHODS: Pretreatment computed tomography was used to measure
      visceral fat area (VFA) and patients with mCRC receiving first-line chemotherapy 
      with/without bevacizumab were divided by median VFA value into two groups: high
      VFA and low VFA. RESULTS: In the bevacizumab-treated group, patients with low VFA
      had significantly shorter overall survival (OS) than patients with high VFA in
      univariate (median=21.1 vs. 38.9 months; hazard ratio=1.70, 95% confidence
      interval=1.06-2.70, p=0.03) and multivariate analysis (hazard ratio=1.85, 95%
      confidence interval=1.15-3.03, p=0.01). No significant differences were seen in
      OS between groups treated with chemotherapy alone. The VFA had a marginally
      significant modifying effect on the relationship between bevacizumab and OS (p
      for interaction=0.07). CONCLUSION: Our findings provide the first evidence that a
      low VFA might be a negative predictive marker for response to bevacizumab in
      patients with mCRC.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Miyamoto, Yuji
AU  - Miyamoto Y
AD  - Department of Gastroenterological Surgery, Graduate School of Medical Sciences,
      Kumamoto University, Kumamoto, Japan.
FAU - Oki, Eiji
AU  - Oki E
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Emi, Yasunori
AU  - Emi Y
AD  - Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
FAU - Tokunaga, Shoji
AU  - Tokunaga S
AD  - Medical Information Center, Kyushu University Hospital, Fukuoka, Japan.
FAU - Shimokawa, Mototsugu
AU  - Shimokawa M
AD  - Department of Cancer Information Research, National Hospital Organization Kyushu 
      Cancer Center, Fukuoka, Japan.
FAU - Ogata, Yutaka
AU  - Ogata Y
AD  - Department of Surgery, Kurume University Medical Center, Kurume, Japan.
FAU - Akagi, Yoshito
AU  - Akagi Y
AD  - Department of Surgery, Kurume University School of Medicine, Kurume, Japan.
FAU - Sakamoto, Yasuo
AU  - Sakamoto Y
AD  - Department of Gastroenterological Surgery, Graduate School of Medical Sciences,
      Kumamoto University, Kumamoto, Japan.
FAU - Tanaka, Takaho
AU  - Tanaka T
AD  - Department of Surgery, Social Insurance Tagawa Hospital, Tagawa, Japan.
FAU - Saeki, Hiroshi
AU  - Saeki H
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Maehara, Yoshihiko
AU  - Maehara Y
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Baba, Hideo
AU  - Baba H
AD  - Department of Gastroenterological Surgery, Graduate School of Medical Sciences,
      Kumamoto University, Kumamoto, Japan [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
OTO - NOTNLM
OT  - Visceral fat
OT  - bevacizumab
OT  - cachexia
OT  - metastatic colorectal cancer
OT  - predictive marker
EDAT- 2017/12/27 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/14 00:00 [received]
PHST- 2017/10/29 00:00 [revised]
PHST- 2017/11/01 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - 38/1/491 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):491-499.